Assembly Biosciences officer proposes $122K share sale

The notice places the approximate sale date on November 2, 2026, and ties the shares to a restricted stock unit release on October 30.

Available on EDGAR 11/02/2026 - 06:30 PM EST Accepted by SEC EDGAR 11/02/2026 - 06:30 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Assembly Biosciences, Inc. (ASMB) reports that Jason A. Okazaki, identified as an officer and director, gave notice of a proposed sale of 6,202 common shares. The notice lists an aggregate market value of $121,657.81, an approximate sale date of November 2, 2026, and Morgan Stanley Smith Barney LLC as broker. The shares were acquired on October 30, 2026, through a restricted stock unit release from Assembly Biosciences.

Key Figures

Shares proposed for sale: 6,202 shares Aggregate market value: $121,657.81 Shares outstanding: 20,476,006 shares +2 more

5 metrics

Shares proposed for sale 6,202 shares Proposed sale

Aggregate market value $121,657.81 Shares proposed for sale

Shares outstanding 20,476,006 shares Common stock

Approximate sale date November 2, 2026 Proposed sale

Acquisition date October 30, 2026 Restricted stock unit release

Key Terms

Restricted Stock Unit Release, Rule 144

2 terms

Restricted Stock Unit Release financial

"10/30/2026 | Restricted Stock Unit Release | Assembly Biosciences, Inc."

Rule 144 regulatory

"the definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ASMB shares does Jason A. Okazaki plan to sell?

Jason A. Okazaki's notice lists a proposed sale of 6,202 shares of Assembly Biosciences common stock, with an aggregate market value of $121,657.81 and an approximate sale date of November 2, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001807214
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Assembly Biosciences, Inc.
SEC File Number	001-35005
Address of Issuer	Two Tower Place, 7th Floor South San Francisco CALIFORNIA 94080
Phone	833-509-4583
Name of Person for Whose Account the Securities are To Be Sold	Jason A. Okazaki
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC 1 New York Plaza 38th Floor New York NY 10004	6202	121657.81	20476006	11/02/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	10/30/2026	Restricted Stock Unit Release	Assembly Biosciences, Inc.			6202	11/02/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	11/02/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jason A. Okazaki
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)